GlassScriptPhysician profile
Rachel E Ortiz
NPI 1730692898
$524.17
in general payments reported to CMS, 2019-2025
14 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.86 · 2023: $204 · 2024: $140 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $129.82 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $83.47 | 2022-2024 | Rexulti |
| Tempus Ai, INC | $51.94 | 2024 | |
| Tris Pharma INC | $43.23 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $42.15 | 2022-2024 | Vivitrol |
| Indivior INC. | $32.34 | 2022-2024 | Sublocade |
| Biogen, INC. | $21.40 | 2023 | |
| Acadia Pharmaceuticals INC | $19.79 | 2022 | |
| Axsome Therapeutics, INC. | $18.28 | 2023 | Auvelity |
| Neos Therapeutics, LP | $17.36 | 2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $17.07 | 2023 | Ingrezza |
| Corium, LLC | $16.44 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $15.87 | 2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.